LRRK2 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK257821A | 1285515-21-0 | sc-396100 | 5 mg | $81.00 | ||
GSK257821A is characterized by its potent reactivity as an acid halide, engaging in acylation processes that yield diverse carbonyl derivatives. Its unique electronic structure enhances electrophilicity, promoting swift nucleophilic attacks. The compound's specific steric hindrance affects the orientation and rate of reactions, leading to tailored product formation. Furthermore, GSK257821A demonstrates a distinctive solubility profile, allowing for optimized interactions in various solvent systems. | ||||||
NVP-BSK805 | 1092499-93-8 | sc-364736 sc-364736A | 5 mg 50 mg | $540.00 $1950.00 | 1 | |
GSK2578215A is a potent and selective LRRK2 inhibitor that directly targets LRRK2 kinase activity, inhibiting its phosphorylation of downstream substrates. | ||||||
LRRK2-IN-1 | 1234480-84-2 | sc-489316 | 10 mg | $245.00 | ||
LRRK2-IN-1 is an ATP-competitive inhibitor that targets the kinase domain of LRRK2, effectively suppressing its kinase activity and subsequent phosphorylation events. | ||||||
N-(2-(2-(2-Methoxy-4-morpholinophenylamino)-5-fluoropyrimidin-4-ylamino)phenyl)methanesulfonamide | 1191911-26-8 | sc-484526 | 10 mg | $430.00 | ||
CZC-25146 is a selective LRRK2 inhibitor that disrupts LRRK2 kinase activity by binding to its ATP-binding pocket, inhibiting substrate phosphorylation. | ||||||
TAE684 | 761439-42-3 | sc-364626 sc-364626A | 5 mg 50 mg | $188.00 $988.00 | 2 | |
TAE684 is a LRRK2 inhibitor that indirectly affects LRRK2 by inhibiting its downstream signaling through the ALK and ROS1 pathways, potentially leading to reduced LRRK2 activity. | ||||||
[4-[[5-Chloro-4-(methylamino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinylmethanone | 1351758-81-0 | sc-505086 | 100 mg | $11500.00 | ||
HG-10-102-01 is an inhibitor of the mTOR pathway, which can indirectly inhibit LRRK2 activity as LRRK2 signaling interacts with the mTOR pathway, potentially reducing LRRK2 activity. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1 is a selective BMP type I receptor kinase inhibitor, indirectly influencing LRRK2 through the BMP signaling pathway, which interacts with LRRK2 signaling, potentially reducing LRRK2 activity. | ||||||
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
BMS-754807 is an IGF-1R inhibitor that indirectly affects LRRK2 by inhibiting the IGF-1R pathway, which can lead to reduced LRRK2 activity due to its interaction with LRRK2 signaling. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
SCH 772984 is a selective ERK inhibitor that indirectly inhibits LRRK2 through the MAPK/ERK pathway, as LRRK2 signaling intersects with this pathway, potentially reducing LRRK2 activity. | ||||||